Latest news and press releases about MediciNova, Inc. (MNOV): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions.
Price
| Price | $2.52 |
| Market Cap | $124M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.65 |
| EV / EBITDA | -5.72 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -26.51% |
| Return on Invested Capital | -31.53% |
| Return on Assets | -26.59% |
| Gross Margin | 42.39% |
| Operating Margin | -1287.41% |
| Net Margin | -1168.20% |
Related companies: ACRV · BMEA · CBUS · FBIO · IMUX · PMVP · RLMD
Explore sector: Healthcare · Biotechnology
More sections of MNOV: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks